Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy regimens: a subgroup analysis from a randomized clinical trial of response in subjects by cancer type

Fig. 3

Kaplan-Meier curves of time to first vomiting episode from the first initiation of MEC for the fosaprepitant regimen versus the control regimen during the overall (0–120 h) phase (ITT population). a Subjects with GI or colorectal cancer. b Subjects with lung cancer. c Subjects with breast cancer. d Subjects with gynecologic cancer. GI gastrointestinal, ITT intent-to-treat, MEC moderately emetogenic chemotherapy

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us